Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pricing Deregulation: 340B Pharmacy Policy, Medicaid Payment Rules May Be Withdrawn

Executive Summary

Trump administration's drug pricing action plan considers withdrawing guidance and whole or parts of rules that biopharma has opposed.


Related Content

Trump Exec Order On Drug Costs: Seeking To Balance Access, Innovation
White House Mulls Proposal To Pause FDA's Quality Metrics Initiative
Trump Administration's Pharma-Friendly Pricing Proposals Prompt Pushback
340B Reform Remains Elusive Even As Spending Increases





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts